Payment overview · 2025
General Payments
$1,218.07
67 reported records · 15 companies
Healthcare provider profile · identity verified
Vikas Varma, MD
Allopathic & Osteopathic Physicians|General Practice · FRESH MEADOWS, NY · NPI 1306870720
Verified facts
What the public records show
CMS Open Payments records show Vikas Varma, MD received $1,218.07 in general payments during 2025 across 67 reported records.
Valinor Pharma, LLC accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Movantik, Nurtec Odt, Qulipta, Ubrelvy, Zavzpret, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZAVZPRET as an associated drug or biological on 140787 records involving 33518 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zavzpret by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ztlido by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $283.39 | 23.3% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $278.02 | 22.8% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.09 | 15.5% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $91.77 | 7.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $88.94 | 7.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.22 | 3.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$45.00 | 3.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.87 | 2.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $31.71 | 2.6% | 1 | 2025 |
| Spinal Simplicity, LLC | Unresolved — no canonical attribution shown | $29.91 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.78 | 2.2% | 1 | 2025 |
| Cerapedics Inc. | Unresolved — no canonical attribution shown | $23.78 | 1.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.62 | 1.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.15 | 1.2% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $13.82 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,218.07 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $283.39 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $278.02 | 20 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $237.74 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.98 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $91.77 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $88.94 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $77.81 | 5 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.22 | 2 | 2025 |
Source payment records
|
|||||
| PIVOX OBLIQUE LATERAL SPINAL SYSTEM Normalized: pivox oblique lateral spinal system |
Device | Medtronic, Inc. | $45.00 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $31.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.11 | 1 | 2025 |
Source payment records
|
|||||
| HA MINUTEMAN G3-R Normalized: ha minuteman g3 r |
Device | Spinal Simplicity, LLC | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| I-FACTOR PEPTIDE ENHANCED BONE GRAFT Normalized: i factor peptide enhanced bone graft |
Device | Cerapedics Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOVANTIK movantik |
2025 | Movantik | 2024 | 250 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 76 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZAVZPRET zavzpret |
2025 | Zavzpret | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ZAVZPRET open payments reported associated product |
CMS Open Payments — General Payments 140787 supporting records · 33518 recipient NPIs · example record 1228794071 |
Zavzpret · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
250 | 102 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1673 | 453 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1599 | 193 |
| Oxycodone Hcl | Oxycodone Hcl | 1209 | 135 |
| Donepezil Hcl | Donepezil Hcl | 784 | 216 |
| Tizanidine Hcl | Tizanidine Hcl | 737 | 220 |
| Meloxicam | Meloxicam | 452 | 193 |
| Zolpidem Tartrate | Zolpidem Tartrate | 389 | 72 |
| Baclofen | Baclofen | 359 | 75 |
| Tramadol Hcl | Tramadol Hcl | 344 | 114 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 294 | 106 |
| Diclofenac Sodium | Diclofenac Sodium | 282 | 90 |
| Movantik | Naloxegol Oxalate | 250 | 102 |
| Pregabalin | Pregabalin | 203 | 49 |
| Lidocaine | Lidocaine | 202 | 58 |
| Rizatriptan | Rizatriptan Benzoate | 183 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 31 |
| Endocet | Oxycodone Hcl/Acetaminophen | 153 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 30 |
| Memantine Hcl | Memantine Hcl | 130 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 126 | 31 |
| Alprazolam | Alprazolam | 125 | 12 |
| Clonazepam | Clonazepam | 124 | 30 |
| Divalproex Sodium Er | Divalproex Sodium | 112 | 31 |
| Entacapone | Entacapone | 112 | 24 |
| Memantine Hcl Er | Memantine Hcl | 109 | 18 |
| Scopolamine | Scopolamine | 109 | 50 |
| Topiramate | Topiramate | 96 | 39 |
| Levetiracetam | Levetiracetam | 95 | 21 |
| Primidone | Primidone | 79 | 23 |
| Ibuprofen | Ibuprofen | 78 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 76 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 29 |
| Clindamycin Hcl | Clindamycin Hcl | 66 | 53 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 57 | 14 |
| Carbamazepine Er | Carbamazepine | 51 | 11 |
| Meclizine Hcl | Meclizine Hcl | 49 | 12 |
| Carisoprodol | Carisoprodol | 43 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 38 | 22 |
| Rivastigmine | Rivastigmine | 35 | suppressed |
| Carbamazepine | Carbamazepine | 34 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Zavzpret | Zavegepant Hcl | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 15 | suppressed |
| Ztlido | Lidocaine | 15 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,218.07 · 67 records | Valinor Pharma, LLC | ELYXYB - CELECOXIB, HA MINUTEMAN G3-R, I-FACTOR PEPTIDE ENHANCED BONE GRAFT, JOURNAVX, KISUNLA, Leqembi, MOVANTIK, NURTEC ODT, PIVOX OBLIQUE LATERAL SPINAL SYSTEM, QULIPTA, RELISTOR, Senza, Symbravo, UBRELVY, VRAYLAR, VYEPTI, WaveWriter Alpha Prime 16, ZAVZPRET, ZTLido | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Movantik play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error